Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNP201
- Development stage
- Unknown
- Lead developer
- SciNeuro Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
SNP201 is a high-affinity monoclonal antibody that targets and inhibits alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. The antibody preferentially binds to aggregated forms of alpha-synuclein, which are known to be pathogenic and are major components of Lewy bodies found in neurodegenerative diseases. By targeting these aggregates, SNP201 aims to clear misfolded proteins through immune therapy and potentially slow or halt neurodegeneration. The drug is being developed by SciNeuro Pharmaceuticals for the treatment of neurological diseases, with its lead indication being Parkinson's disease[1][2][3][4][6].
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))
Beyond the preview
Go deeper on SNP201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNP201.